anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HDL, or good cholesterol, has been shown to protect against heart attack and stroke. How HDL works as a protective agent is not well understood. There is a family that has 4 generations of living members with high HDL level. In the study, after consent is obtained, we will obtain 2 tablespoons of blood from all the family members in order to study their cholesterol levels and to obtain DNA in order to determine if there is a pattern of inheritance for this trait. We will also have them fill out a questionnaire about their medical history, diet and activity level as all of these can affect their HDL levels. In addition we will obtain additional blood (about 2 tablespoons) for plasma, white blood cells and also perform a biopsy to obtain skin cells from a matched pair of family members with and without the trait in order to determine which genes might be turned on and off because of this trait. We also wish to study other families who have members with high HDL cholesterol as well. These individuals will be identified from a core database.
Cardiac pacing which involved stimulating the heart electrically with electrical wires that go into the heart is routine practice in the diagnosis and treatment of heart rhythm problems. Clinically this involved the fields of cardiac pacing and electrophysiology. Patients who are at risk of sudden death because of serious heart rhythms that are a result of malfunction of the electrical system of the pumping chambers of the heart (ventricles) are generally implanted with specialised pacemakers that can defibrillate (shock) the heart if a nasty life threatening rhythm should result. Shocks are painful and in order to try and treat these rhythms without shocks, anti tachycardia pacing is performed (this is routine part of the device), which aims to interrupt the rhythm by stimulating the heart electrically. This does not always work and can destabilise the rhythm leading to a shock. REVRAMP is a novel modification of anti tachycardia pacing which involved stimulating the heart through the defibrillator wires in a different way. It appears to work better and seems less likely to destabilise the heart rhythm, hence can reduce painful shocks.
Materials and Methods Collection of blood samples Blood samples of 240 healthy children will be obtained from the blood that will be collected for the routine coagulation screening (in neonates and in children \< 18 months) or at the time of surgery in children aged \> 18 months. Healthy neonates will be recruited by the neonatologists. Children aged from 1 month to 15 years will be included by anesthesiologists before minor elective surgery such as tonsillectomy, adenoidectomy, phimosis or oral surgery. Additionally, blood from adults referred for thrombophilia testing will be studied. This study was approved by French authorities (ANSM and CPP). Inform consent will be obtained from all participants. Blood will be collected into plastic tubes containing sodium citrate (0.106 M, tubes from "Starstedt"). Platelet poor plasma will be obtained by two centrifugations for 10 minutes at 2500 g at room temperature and stored at - 70°C until further examination.

Statistical analysis Statistical analysis will be performed as 1) a descriptive analysis (frequency and percentage for qualitative data, mean, SD and centiles for quantitative data), and 2) a comparison analysis (student, Mann-Withney, Kruskall- Wallis).
This will be a prospective cohort study to evaluate 1) the feasibility and acceptability of using standardized educational and communication tools to assist in communication of genetic test results to family members, 2) utility of the communication tool, and 3) the impact of a patient focused information sheet on the knowledge of genetic testing in women who attend the women's oncology clinic. Genetic counseling is recommended for all women with a diagnosis of ovarian cancer, most patients with pre-menopausal diagnosis of breast cancer, and in younger women with uterine or other gynecologic malignancies. Women with a diagnosis of breast or gynecologic cancer who elect to undergo genetic testing will be approached to participate in this study. If they consent, they will be provided with two information handouts (FORCE sharing worksheets) and family letter template. Participants will complete a baseline knowledge survey prior to receipt of these materials. At a second visit, they will complete the knowledge survey again. Knowledge surveys will be scored and pre and post test scores will be compared with a paired t-test. Feasibility will be assessed by tracking the number of patients approached to participate, the number who sign consents, and the number who complete the study.
NEW MATERIAL:A polypeptide expressed by formula I [left end is amino terminal and right end is carboxyl terminal; m, n, p and q represent 0 or 1; A-F represent an amino acid (sequence) region respectively corresponding to the following amino acid number, A: number 1, B: number 2-20, C: number 21, D: number 22-237, E: number 238-298, F: number 299-363]. USE:An activator for biophylaxis such as immune response, differential proliferation, etc. PREPARATION:For example, a human leukocyte is cultured with a differentiation inducer and an mRNA fraction is separated from the cell. A cDNA library is prepared by using the mRNA as a template. Then the cDNA is cloned from this library with a colony hybridization method, etc., and the cDNA is combined with an expression vector and introduced into a host cell to transform. The transformed host cell is cultured to provide the polypeptide expressed by formula I.
NEW MATERIAL:A benzimidazole of formula I (R1 and R2 are mutually independently H or lower alkyl). EXAMPLE:2-(2-Methylaminobenzylsulfinyl)benzimidazole. USE:Useful as an antiulcer agent. The compound exhibits a gastric acid secretion- inhibiting action based on the excellent H<+>+K<+>ATPase-inhibiting action thereof. PREPARATION:A 2-mercaptoimidazole of formula II is subjected to a reaction with a 2-aminobenzyl compound of formula III (X is a reactive group) preferably in the presence of an alkaline agent such as sodium hydroxide in a solvent such as toluene at the room temperature to the refluxing temperature of the solution to prepare a compound of formula VI. The compound of the formula VI is oxidized with an oxidizing agent such as hydrogen peroxide in a solvent such as chloroform at -30 deg.C to 50 deg.C to provide the compound of formula I.
A controlled release medicament delivery system comprises a plasticized or unplasticized bioerodible polymer, such as a polyorthoester, suspended as a discontinuous phase in a hydrophobic liquid such as silicone oil or mineral oil as a continuous phase. Medicament desirably is entrapped at least partly by the discontinuous phase. The resulting delivery system is able to release the medicament in a controlled and sustainded manner. The formulation is particularly advantageous for use as a once-a-day eyedrop. During preparation, the polymer may be heated to an elevated temperature for a sufficient time to substantially reduce its molecular weight. Medicament may be added at a temperature above which there is complete phase separation.
PURPOSE: To obtain a partly N-acylated chitooloigosaccharide or its salt which is water-sol., can retain a high amt. of water, has surface-active properties, and is useful as an antibacterial agent and a cosmetic additive by selecting a specific partly N-acylated chitooligosaccharide or its salt. CONSTITUTION: A partly N-acylated chitooligosaccharide or its salt is selected which comprises 5-80% acylglucosamine units represented by formula I (wherein COR is a 4-26C acyl), 20-95% glucosamine units represented by formula II, and 0-50% acetylglucosamine units represented by formula III and in which the sum of those three kinds of units is 3-20, pref. 3-9, still pref. 6-9. This compd. is obtd. e.g. by hydrolyzing chitin under an alkaline condition, hydrolyzing the resultant chitosan under an acidic condition, and acylating the resultant chitooligosaccharide with a usual acylating agent.
Participants will receive CBT, which will consist of in-person and computer-based component (based on Good Days Ahead). This will consist of 20 sessions given over 16 weeks.
The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
Current HIV treatment guidelines recommend the construction of combination regimens comprising a minimum of three agents from at least two drug classes. There are problems with the current recommendations for although treatments are effective, their success is often limited by tolerability, adverse effects and the need to take many pills. Antiretroviral adherence remains vital and regimens should be simplified wherever possible to facilitate maximal adherence. The recent availability of the potent HIV integrase inhibitor, raltegravir, provides an opportunity to explore moves away from current regimen components. Evidence to support the use of novel regimens must be generated through adequately powered randomized clinical trials. However, before such trials can be undertaken, preliminary data to define the pharmacokinetics, safety and tolerability of these regimens are needed to minimize unnecessary risk for participants. This eight week study will investigate the steady-state pharmacokinetics, and short-term safety and efficacy of two dosing strategies (once and twice daily) of raltegravir plus atazanavir in treatment experienced HIV-infected adults.
Neuroinflammation is a pathological hallmark of Alzheimer's disease (AD), characterized by the stimulation of resident immune cells of the brain and the penetration of peripheral immune cells. These inflammatory processes facilitate the deposition of amyloid-beta (Aβ) plaques and the abnormal hyperphosphorylation of tau protein. Managing neuroinflammation to restore immune homeostasis and decrease neuronal damage is a therapeutic approach for AD. One way to achieve this is through exercise, which can improve brain function and protect against neuroinflammation, oxidative stress, and synaptic dysfunction in AD models. The neuroprotective impact of exercise is regulated by various molecular factors that can be activated in the same way as exercise by the administration of their mimetics. Recent evidence has proven some exercise mimetics effective in alleviating neuroinflammation and AD, and, additionally, they are a helpful alternative option for patients who are unable to perform regular physical exercise to manage neurodegenerative disorders. This review focuses on the current state of knowledge on exercise mimetics, including their efficacy, regulatory mechanisms, progress, challenges, limitations, and future guidance for their application in AD therapy.
Celiac disease (CeD) is a common food-induced inflammatory disease of the small intestine caused by the ingestion of gluten from wheat, barley and rye. It is one of the most prevalent food hypersensitivities worldwide and affects 0.5-2.5% of the European population. The only effective treatment available is a strict lifelong gluten-free (GF) diet. GF products for CeD patients must not exceed the regulatory threshold of 20 mg/kg of gluten. Compliance of foods containing fermented or partially hydrolysed gluten is routinely assessed using the R5 competitive enzyme-linked immunosorbent assay (ELISA). However, this test does not adequately represent gluten immunogenicity in CeD patients. The overall objective of our ImmunoSafe-CeD proposal is to determine the CeD immunogenic activity of intact and partially hydrolysed gluten from wheat, rye and barley and develop improved comprehensive functional and analytical assays, including novel ELISAs and quantitative proteomics methods to ensure food safety for CeD patients. Thus, our objective is designed to directly address the needs of the CeD community about being reassured that GF products that contain partially hydrolysed gluten are safe and suitable for inclusion in their GF diet. By combining discovery proteomics and quantitative LC-MS/MS methods, improved reference materials for partially hydrolysed gluten, CeD-patient derived monoclonal antibodies and functional gluten-specific T-cell assays, we will provide a comprehensive and unique toolbox of novel and validated methods to detect gluten (both intact and partially hydrolysed) in foods for CeD patients.

This toolbox will close the current discrepancy between food analytical methods and CeD immunogenicity for the first time, because all methods will be matched to clinical pathophysiology assessed by food challenge in CeD patients. Our multidisciplinary consortium is built on previous highly successful collaborations and we are well-positioned to create even more synergies between us by exchanging materials, know-how and data. We expect to 1) better understand the role that the different glutens play in CeD pathogenesis, 2) develop easy-to-perform and reliable analytical tools (ELISA) that quantitate and predict immunogenicity (toxicity) of wheat, rye and barley products for CeD patients, and 3) define foods that CeD patients can tolerate despite being partly based on these processed grains
The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
DAS181 4.5mg/day or 9mg/day. Dosage will be determined after completion of stage 1.
FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition has hydrophilic and lipophilic phases. Hydrophilic phase has water and biologically active substance bound as noncovalent complex with lecithin or lecithin precursor in vivo. Lipophilic phase has compound forming chylomicrons matrix, lecithin or phospholipid and lipophilic surface-active substance. Volume ratio of hydrophilic and lipophilic phase = (0.2:1)-(5:1). Biologically active substance is a protein taken from group involving insulin, erythropoietin, pig somatotropin, human growth hormone and salmon calcitonine. Method of preparing pharmaceutical composition involves preparing hydrophilic and lipophilic phases which were mixed thoroughly obtaining nonliposomal composition. EFFECT: improved method of preparing. 25 cl, 13 tbl, 10 dwg
The invention discloses a composition and a preparation for breast cancer hydrothorax/ascites and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. The composition is prepared from radix Glycyrrhizae Preparata, radix Codonopsis, bupleuri radix, vinegar-processed rhizoma corydalis, radix Curcumae, bulbus Fritillariae Thunbergii, parched fructus Hordei Germinatus, herba Hedyotidis Diffusae, cortex Albiziae, fructus Citri Sarcodactylis, rhizoma paridis, fructus Toosendan, herba Solani Lyrati, catechu, herba Duchesneae Indicae and rhizoma Pinelliae. The formulation principle of the prescription is based on the syndrome of liver depression transforming into fire. The composition is mainly used for treating breast cancer, hydrothorax and ascites, liver depression transforming into fire, and damp-heat accumulating in spleen. The formula mechanism is as follows: the hedyotis diffusa has the effects of clearing heat and promoting diuresis and is a monarch drug; the Indian mockstrawberry herb, the catechu, the solanum dulcamara and the paris polyphylla are used as ministerial drugs for clearing damp and heat; fructus Toosendan, cortex Albiziae, radix bupleuri, radix Curcumae, fructus Citri Sarcodactylis, and dispersing stagnated liver qi; corydalis tuber, rhizoma corydalis, has the effects of promoting qi circulation and relieving pain by promoting qi circulation and qi stagnation in blood; ginger processed pinellia tuber, dampness eliminating and phlegm resolving; radix codonopsis, for strengthening the middle-jiao and replenishing qi; fritillary bulb, rhizoma fritillariae thunbergii, which can clear heat and dissipate nodulation, and is used as an adjuvant drug; prepared licorice root, radix Glycyrrhizae Praeparata, as a guiding drug, regulates the action of other drugs. The efficacy of the formula is as follows: liver soothing, heat expelling, blood circulation activating, pain relieving, and damp heat removing.
Consented patients randomized to the control group will receive usual care at MSK. This will comprise standardized verbal (and sometimes also written) instructions about Kegel exercises from the nurse and/or urologist before the operation. All patients will complete the Prostate Quality of Life Survey at baseline and at 1.5, 3, and 6 months after radical prostatectomy (within ±2 weeks is considered acceptable to avoid protocol violations). This is part of the standard of care for patients undergoing prostatectomy.
PURPOSE: Metabolic surgery remains underutilized for treating type 2 diabetes, as less invasive alternative interventions with improved risk profiles are needed. We conducted a pilot study to evaluate the feasibility of a novel magnetic compression device to create a patent limited caliber side-to-side jejunoileal partial diversion in a nonhuman primate model.
MATERIALS AND METHODS: Using an established nonhuman primate model of diet-induced insulin resistance, a magnetic compression device was used to create a side-to-side jejunoileal anastomosis. Primary outcomes evaluated feasibility (e.g., device mating and anastomosis patency) and safety (e.g., device-related complications). Secondary outcomes evaluated the device's ability to produce metabolic changes associated with jejunoileal partial diversion (e.g., homeostatic model assessment of insulin resistance [HOMA-IR] and body weight).
RESULTS: Device mating, spontaneous detachment, and excretion occurred in all animals (n = 5). There were no device-related adverse events. Upon completion of the study, ex vivo anastomoses were widely patent with healthy mucosa and no evidence of stricture. At 6 weeks post-device placement, HOMA-IR improved to below baseline values (p < 0.05). Total weight also decreased in a linear fashion (R2 = 0.97) with total weight loss at 6 weeks post-device placement of 14.4% (p < 0.05).
CONCLUSION: The use of this novel magnetic compression device to create a limited caliber side-to-side jejunoileal anastomosis is safe and likely feasible in a nonhuman primate model. The observed glucoregulatory and metabolic effects of a partial jejunoileal bypass with this device warrant further investigation to validate the long-term glucometabolic impact of this approach.
This is a modular, phase I, two part, open-label, multicentre study of ceralasertib, administered orally, in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced/metastatic solid malignancies. The study design allows an escalation of the dose of ceralasertib in combination with the standard dose and schedule of either cytotoxic chemotherapies and/or novel anti-cancer agents, with intensive safety monitoring to ensure the safety of the patients. There are two parts to each combination module of this study; part A, dose escalation and an optional part B, cohort expansions in particular patient groups. The initial combination module will be with Carboplatin (module 1). The second combination will be with Olaparib (module 2). The third combination will be with durvalumab (module 3), the fourth combination will be AZD5305 (Module 5). The option to start further combination modules will be the decision of the Safety Review Committee (SRC), based on emerging preclinical data and, safety and tolerability information from the initial combination. Combinations of ceralasertib with novel anti-cancer agents may also be explored. Once a minimally biologically active dose of ceralasertib, for that combination module, has been identified from part A of that module, the SRC may decide to commence part B if deemed to be necessary. This may include cohort expansions of specific patient groups to explore preliminary anti-tumour activity or the effect of food or particular drug combinations on drug pharmacokinetics. The fourth module will investigate the effect of food on ceralasertib absorption and whether ceralasertib has an effect on QT.
The present invention relates to a cosmetic composition comprising a spiderweb peptide having 10 to 70 KDa of molecular weight or a spiderweb hydrolysate yielded by hydrolyzing the spiderweb through fermenting Laetiporus sulphureus var. miniatus (Jungh.) Imaz. as an active ingredient. The spiderweb peptide having 10 to 70 KDa of molecular weight or a spiderweb hydrolysate yielded by hydrolyzing the spiderweb through fermenting Laetiporus sulphureus var. miniatus (Jungh.) Imaz. shows an excellent antioxidant activity, a MMP-1 inhibitory effect, a collagen synthesis promoting effect, and an elastase inhibitory effect. The spiderweb peptide or the cosmetic composition comprising the spiderweb hydrolysate as an active ingredient of the present invention shows an excellent skin moisturizing effect, a skin elasticity promoting effect and a wrinkle improvement effect.
Tocilizumab will be provided in prefilled syringes (162 mg tocilizumab/0.9 mL solution). All participants randomized to tocilizumab in the first or second stage randomization will be receiving 1 prefilled syringe (162 mg) with a dosing interval based on the body weight criteria.
DRE patients with proved vitamin D deficiency (Serum vitamin D level \<30ng/ml). intervention: Daily Cholecalciferol 1000 IU in 24 weeks.
Participants in the telehealth-based model will undergo occupational therapy treatment via a telehealth-based video chat platform for the entire episode of care (generally 10-12 weeks in duration). The patient will use the video chat client to connect to his/her occupational therapist, and the therapist will conduct the session over this virtual connection.
Pulmonary arterial hypertension (PAH) is a disease characterized by pulmonary vascular remodeling. Since dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP) is associated with cardiovascular mortality in systemic sclerosis, a disease associated with PAH, and immune-system involvement in PAH is increasingly recognized, we investigated the relationship between dp-ucMGP, vascular remodeling and soluble immune-checkpoint proteins in PAH. This prospective cohort study included patients with idiopathic (I)PAH, connective tissue disease (CTD)-PAH, chronic thrombo-embolic PH (CTEPH) and CTD patients without PAH. Patients with IPAH and CTD-PAH were stratified by clinical signs of immune-mediated inflammatory disease (IMID). We measured dp-ucMGP plasma levels, soluble immune-checkpoint proteins (sICPs), and vascular smooth muscle cell (iVSMC) calcification. We found elevated dp-ucMGP levels in all PAH subtypes and CTD patients compared to healthy controls. PAH patients showed increased iVSMC calcification, but no direct correlation was found with dp-ucMGP. IMID-PAH patients had higher dp-ucMGP levels than non-IMID PAH patients. dp-ucMGP correlated with several sICPs in both IPAH and CTD patients; multiple sICPs were elevated in IMID PAH patients. High dp-ucMGP levels in IPAH patients were associated with worse survival. Our findings suggest dp-ucMGP as a potential biomarker of immune-mediated vascular remodeling in PAH. Hence, dp-ucMGP, could help identify PAH patients who might benefit from immunosuppressive therapies.